There has been recent interest in folate/folic acid, the potential effect on PCa proliferation, & the possible benefit of insufficiency. The focus has been on the SAM cycle. Folate/folic acid is a methyl donor in the SAM cycle. SAM delivers methyl to cells that want it. PCa cells are avid methyl users. Hypermethylation in PCa cells silence tumor suppressor genes.
But there is another angle to the folate problem.
Folate is the natural ligand for the folate receptor [FR], but folic acid readily binds to FR too.
When cancer cells rapidy divide they have an increased need for folate. To meet this need, cells will increase the expression of FR on their surface.
In a recent paper that looked at FR expression in circulating PCa cells [1]:
"Folate-receptor positive circulating tumor cells (FR+CTCs) shows an important role in the diagnosis and dynamic monitoring for many solid tumors; however, the application of FR+CTCs in prostate cancer remains unclear." {How come?}
"... FR+CTCs level was consistently high in the prostate cancer patients with different tPSA levels .., and it was significantly higher in the patients with f/tPSA levels <0.16 than in those patients with f/tPSA levels >0.16 ..."
The authors were concerned with FR+CTCs for early diagnosis, but measurement of FR levels in CTCs could identify men who might respond to FR-based therapy.
From an early paper on the subject (Endocyte, US; Israel [2014]) [2]:
"The folate receptor (FR) has been identified as a new molecularly targeted entity, which is highly overexpressed on the surface of a spectrum of solid tumor cells, including ovarian, kidney, lung, brain, endometrial, colorectal, pancreatic, gastric, prostate, testicular, bladder, head and neck, breast, and non-small cell lung cancer. Folic acid conjugation is a novel approach for targeting FR-expressing tissues for personalized treatment."
Endocyte is the developer of Vintafolide {& of "Technetium (99mTc) etarfolatide ... an investigational non-invasive, folate receptor-targeting companion imaging agent" [3]}.
"Vintafolide is designed to deliver the toxic vinblastine drug selectively to cells expressing the folate receptor using folate targeting." [4]
Clearly, for folate plus a lethal conjugate to work, without wiping out normal cells, a minimum number of FRs is required on the target cells. The therapy would thus target only the most aggressive cells. Hopefully with minimal toxicity.
Anyway, the point of this post is that we need to be wary of folic acid in supplements and fortified food. I don't suppose that many of us will overdose on folate from leafy greens, but aggressive PCa needs folate. Flirting with deficiency might slow it down.
This is not medical advice, ot course. For folate deficiency, see: [5].
-Patrick
[1] ncbi.nlm.nih.gov/pmc/articl...
[2] pubmed.ncbi.nlm.nih.gov/254...
[3] en.wikipedia.org/wiki/Techn...